PA
ALXN

Perceptive Advisors’s Alexion Pharmaceuticals ALXN Stock Holding History

Perceptive Advisors’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-463,450
Closed -$57.5M – 145
2018
Q2 		$57.5M Sell
463,450
-410,000
-47% -$47.9M 1.51% 17
2018
Q1 		$97.4M Buy
+873,450
New +$104M 2.73% 8

Other funds holding ALXN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Perceptive Advisors's ALXN Position: Q3 2018 in Review

Perceptive Advisors sold out of Alexion Pharmaceuticals (ALXN) in Q3 2018, closing a stake of 463,450 shares — an estimated $57.5M sold.

Perceptive Advisors first reported a position in ALXN in Q1 2018 and held it in 2 quarters. The position peaked at $97.4M in Q1 2018. 584 funds tracked by Wall St. Rank hold ALXN as of Q3 2018.

  • Perceptive Advisors reported no remaining Alexion Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
  • Perceptive Advisors sold 463,450 Alexion Pharmaceuticals shares in Q3 2018, an estimated $57.5M.
  • Perceptive Advisors first reported a position in Alexion Pharmaceuticals in Q1 2018 and held it in 2 quarters.
  • Perceptive Advisors's Alexion Pharmaceuticals position peaked at $97.4M in Q1 2018.
  • 584 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2018.

Based on Perceptive Advisors's 13F filing for Q3 2018, filed 14 Nov 2018.